Looking for advice from my fellow NET warriors. I had surgery/ablations for my small-bowel NET liver mets in July...

Guidance for Your Small-Bowel NET with Liver Metastases

I can see you're gathering information before your September appointment—that's excellent preparation. Let me address your questions systematically using current evidence-based guidelines for well-differentiated small-bowel NETs with liver metastases.

---

1) Treatment Options for Well-Differentiated Small-Bowel NETs with Liver Mets

Your situation is common enough that there's solid guidance. According to NCCN Guidelines for Neuroendocrine Tumors, patients with your profile (well-differentiated, liver-predominant disease, stable small lesions) have several established options:

Your Current Status Matters

• Asymptomatic, low tumor burden, stable disease: Observation with serial imaging is a legitimate first option
• Progressive disease or symptomatic: Treatment escalation is recommended

Since your June MRI showed stable lesions and you're feeling well, your oncologist may recommend surveillance first—but this is individualized.

---

2) Somatostatin Analogs (Octreotide LAR/Lanreotide)

What the evidence shows:

According to NCCN Guidelines, octreotide LAR or lanreotide are preferred first-line therapies for:

• Controlling hormone symptoms (though your hot flashes may or may not be NET-related)
• Slowing tumor growth in well-differentiated NETs
• Standard dosing: octreotide LAR 20-30 mg IM monthly or lanreotide 120 mg SC every 4 weeks

Key point from guidelines: These work best if your tumors are SSTR-positive (somatostatin receptor positive). Your DOTATATE PET scan essentially confirms this—the uptake means your tumors express these receptors, making SSAs a good option for you.

Side effects (generally mild):

• Injection site reactions
• GI symptoms (diarrhea, constipation)
• Gallstones (long-term risk—some patients get prophylactic cholecystectomy)
• Fatigue (uncommon)

Important: If you start SSAs, the NCCN Guidelines note that some patients need dose escalation over time. Above-label dosing (up to 60 mg octreotide LAR monthly) has been used in selected cases.

---

3) PRRT with Lutetium Lu 177 Dotatate (Lutathera)

This is where the most exciting recent data comes in for your situation.

NETTER-2 Trial Results (2024)

According to NCCN Guidelines citing the NETTER-2 study, this radiopharmaceutical therapy showed remarkable results:

• Progression-free survival: 22.8 months (Lutathera + octreotide) vs. 8.5 months (octreotide alone)
• Overall response rate: 65% with Lutathera combination vs. 7% with octreotide alone
• 72% reduction in risk of disease progression or death

When PRRT is Recommended

According to NCCN Guidelines, PRRT with lutetium Lu 177 dotatate is a Category 1 preferred option for:

• SSTR-positive tumors (✓ you have this)
• Progressive disease on octreotide LAR/lanreotide
• Intermediate to high-risk disease (Ki-67 10-55%)

Important caveat: NETTER-2 enrolled patients with progressive disease. Your tumors are currently stable, so your oncologist may recommend:

1. Starting SSAs first to see if they control growth
2. Reserving PRRT for if/when progression occurs
3. Or proceeding to PRRT now if your Ki-67 is elevated (you didn't mention this—ask your oncologist)

PRRT Side Effects (from NETTER-2):

• Fatigue (7%)
• Decreased blood counts (12%)
• Hypertension (12%)
• Rare: myelodysplasia (1 case noted in long-term follow-up)
• Generally well-tolerated compared to chemotherapy

Practical details: PRRT requires IV amino acid infusion for kidney protection and is given every 8 weeks for 4 cycles typically.

---

4) Liver-Directed Therapies (Ablation, Embolization, Histotripsy)

This is where your question gets really specific. Let me break down what's available:

A) Radiofrequency Ablation (RFA) & Cryoablation

You've already had ablations—good choice for small lesions.

NCCN Guidelines state:

• Recommended for oligometastatic liver disease (generally ≤4 lesions, each <3 cm)
• Your lesions fit this profile perfectly (1.2 cm, 0.7 cm, 0.6 cm, 0.6 cm)
• Can be repeated if new lesions develop
• Symptom palliation in ~85% of patients with hormonal syndromes

Why you might consider repeat ablation: If these lesions progress, RFA/cryoablation are low-risk options before systemic therapy.

B) Transarterial Embolization (TAE) & TACE

NCCN Guidelines recommend for:

• Liver-predominant, unresectable disease
• Symptomatic or progressive disease
• Objective response rates: ~60% radiologic response
• Symptom palliation: ~85% in hormonal syndromes

Side effects: Post-embolization syndrome (pain, nausea), risk of liver abscess (~20% with TAE/TACE, lower with TARE)

C) Transarterial Radioembolization (TARE)

• Better tolerated than TAE/TACE
• Lower infection risk (8% vs. 20%)
• Concern: late radioembolization-induced chronic hepatotoxicity in long-term survivors
• Unknown: Safety of sequencing TARE with PRRT (per NCCN Guidelines)

D) Histotripsy for Liver Mets

This is where I need to be honest with you: I don't have specific NCCN or major guideline data on histotripsy for NET liver metastases in my knowledge base.

Histotripsy is an emerging technology using ultrasound to mechanically destroy tissue. While it shows promise in some tumor types, I cannot find published evidence specifically for NET liver mets in the authoritative sources I'm using.

What I'd recommend: Ask your NET oncologist specifically about:

• Whether they have experience with histotripsy for NETs
• If there are clinical trials available
• How it compares to RFA/cryoablation for your specific lesion sizes
• Whether it's available at your cancer center

This would be an excellent question for your September 17 appointment.

---

5) Capecitabine + Temozolomide (Cap-Tem)

What the evidence shows:

According to NCCN Guidelines, Cap-Tem is listed as a cytotoxic chemotherapy option for:

• Advanced GI NETs with progressive disease
• Particularly more effective in pancreatic NETs than small-bowel NETs
• Response rates in small-bowel NETs are modest

Important Context

The guidelines note: "The benefits associated with cytotoxic chemotherapy in patients with advanced GI NETs appear, at best, to be modest. Tumor response rates are generally low."

For small-bowel NETs specifically:

• FOLFOX showed 12.5% partial response rate
• Cap-Tem data in small-bowel NETs is limited
• Generally reserved for progressive disease when other options exhausted

Side Effects of Cap-Tem

• Bone marrow suppression (low blood counts)
• Nausea/vomiting
• Diarrhea
• Fatigue
• Hand-foot syndrome (capecitabine)
• Requires monitoring with blood work

When it's used: Typically for progressive, high-burden disease—not usually first-line for stable, small lesions like yours.

---

6) Suggested Treatment Approach for YOUR Situation

Based on NCCN Guidelines and